Tempus AI announced a collaboration with SOTERIA focused on precision oncology for U.S. military members and veterans with cancer.
The company said the collaboration aims to advance precision oncology for this group. The Nov. 9 headline states the focus, but the available information does not explain the terms, timeline, or financial impact.
Investor takeaway: The collaboration sets a focus on precision oncology for military members and veterans. Its scope and commercial implications remain unclear.
Tempus AI, Inc. Class A Common Stock
TEM.US
TEM.US
Tempus AI, Inc. Class A Common Stock
WealthAwesomeMarket cap
$15.40B
52W high
$89.09
52W low
$40.77
1W change
+7.59%
Beta
3.61
Analyst Price Targets
Based on 20 analysts covering TEM · as of Nov 9, 2026
Wall Street analysts forecast TEM stock price to rise 6.1% over the next 12 months.
Consensus
Buy3.90 / 5.00
Avg. Target
C$89.56
+6.1% Upside
Previously C$82.89 on Nov 5, 2026
Current Price
C$84.44
Last close
Analyst Breakdown (20 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TEM's historical volatility
30-Day Vol
94.1%
Annualized
90-Day Vol
91.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$100.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$89.62 | C$64.78 – C$123.99 |
| 60 trading days | C$95.12 | C$60.10 – C$150.53 |
| 90 trading days | C$100.95 | C$57.53 – C$177.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Tempus closed at US$80.63
The shares gained 11.03% in one day. Latest volume was 1,783,790 shares, below the 20-day average of 6,356,445.
Bull case
The collaboration connects Tempus with an initiative focused on precision oncology for a specific patient population.
Bear case
The announcement gives no details about the collaboration’s activities, scale, timing, or expected contribution to Tempus’s business.
What happened: Tempus announced a SOTERIA collaboration
A Nov. 9 company-news headline says Tempus is working with SOTERIA to advance precision oncology for U.S. military members and veterans with cancer. The available information does not say what either organization will do, which services or technologies are involved, or when the collaboration will begin. It also gives no details about funding, patient numbers, or expected revenue. For now, the announcement identifies a collaboration and its focus, but does not quantify the business opportunity. See the Tempus stock page.
What the numbers show: the share move and trading volume
Tempus closed at US$80.63, up 11.03% for the day and 7.59% for the week, based on the supplied figures. Latest volume was 1,783,790 shares, compared with a 20-day average of 6,356,445. The data also report volume at 1.27 times the average. They do not show that the SOTERIA announcement caused the share-price move.
Tempus reported a market capitalization of about US$15.4 billion, trailing-twelve-month EPS of -US$1.18, and a profit margin of -12.5%. These figures provide company context, but they do not show the collaboration’s potential impact. See the TEM stock page.
What to watch next: details on scope and execution
Investors will need more information about the collaboration’s activities, timing, participating organizations, and measurable patient or business outcomes. None of those details appears in the available announcement facts, so its scale and financial contribution remain unclear. Tempus’s other listed headlines include Q3 earnings coverage dated Nov. 3, but those reports do not provide details about the SOTERIA collaboration.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
